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Abstract
Background: We studied the benefit of using in vitro matured metaphase I (MI) oocytes for ICSI
in patients with a maximum of 6 mature metaphase II (MII) oocytes at retrieval.
Methods: In 2004, 187 ICSI cycles were selected in which maximum 6 MII oocytes and at least
one MI oocyte were retrieved. MI oocytes were put in culture to mature until the moment of ICSI,
which was performed between 2 to 11 hours after oocyte retrieval (day 0). In exceptional cases,
when the patient did not have any mature oocyte at the scheduled time of ICSI, MI oocytes were
left to mature overnight and were injected between 19 to 26 hours after retrieval (day 1). Embryos
from MI oocytes were chosen for transfer only when no other good quality embryos from MII
oocytes were available. Outcome parameters were time period of in vitro maturation (IVM), IVM
and fertilization rates, embryo development, clinical pregnancy rates, implantation rates and total
MI oocyte utilization rate.
Results: The overall IVM rate was 43%. IVM oocytes had lower fertilization rates compared to in
vivo matured sibling oocytes (52% versus 68%, P < 0.05). The proportion of poor quality embryos
was significantly higher in IVM derived oocytes. One pregnancy and live birth was obtained out of
13 transfers of embryos exclusively derived from IVM oocytes. This baby originated from an oocyte
that was injected after 22 hrs of IVM.
Conclusion: Fertilization of in vitro matured MI oocytes can result in normal embryos and
pregnancy, making IVM worthwhile, particularly when few MII oocytes are obtained at retrieval.
Background
A proportion of human oocytes collected during an IVF or
ICSI procedure remains meiotically immature at the ger-
minal vesicle (GV) or metaphase I (MI) stage. Several pub-
lications have shown that this proportion fluctuates
around 15 to 20% [1,2]. It is not exactly known why some
of the oocytes are unresponsive to the maturation trigger
in vivo. Different explanations are possible. When ovarian
hyperstimulation is started, follicles may be at different
stages of development, producing oocytes of varying
degrees of maturity. Since follicles are aspirated prior to
rupture, the collected oocytes come from a heterogeneous
pool of follicles, including luteinizing as well as degener-
ating follicles [3]. It is also possible that smaller antral fol-
licles are aspirated during oocyte retrieval, which can
result in the collection of immature oocytes [4,5]. Eventu-
ally, the proportion of immature oocytes can be depend-
ent on patients' characteristics (such as cause of infertility,
age, ovarian reserve) and the stimulation protocol used.
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Immature oocytes from superovulated cycles can undergo
the final stages of meiotic maturation spontaneously in
vitro. MI oocytes have already undergone the process of
germinal vesicle breakdown (GVBD) and may progress to
the metaphase II (MII) stage within a few hours of in vitro
culture. This allows them to be injected by ICSI at the
same time as their sibling mature MII oocytes. The clinical
use of MI oocytes from stimulated cycles has been studied
by several research groups. It has been reported that these
in vitro matured oocytes yield lower fertilization rates [6-
8], abnormal embryonic development [7-9] and lower
implantation rates [6] than in vivo matured oocytes.
Development to term is limited to rare cases [6,8,9]. As a
consequence, immature oocytes from stimulated cycles
are generally considered to be a side-product and only in
vivo matured MII oocytes are used for ICSI. Nevertheless,
for patients in whom a low number of MII oocytes are
retrieved, the use of in vitro matured MI oocytes may be
worthwhile in order to increase the number of injectable
oocytes at the time of ICSI.
We therefore designed the present study to determine if,
indeed, in vitro matured MI oocytes could have a clinical
application in our IVF-program in a selected population
of patients with a low number of MII oocytes at retrieval.
This was analyzed within the framework of a daily labora-
tory practice, without changing the routine of ovarian
stimulation, oocyte retrieval, ICSI procedure, embryo cul-
ture or transfer.
Methods
Patient selection
The study included all ICSI cycles over a one year period
(2004) in which two inclusion criteria were fulfilled: 1) a
maximum of 6 mature (MII) oocytes and 2) at least one
MI oocyte present at retrieval.
Our ICSI program has been approved as infertility treat-
ment by the Ghent University Hospital Ethical Commit-
tee.
Ovarian stimulation, IVM and oocyte handling for ICSI
All patients underwent controlled ovarian stimulation
after cycle synchronization with a standard contraceptive
pill for 2–6 weeks. A short gonadotrophin-releasing hor-
mone (GnRH) agonist protocol was used, consisting of
0.1 mg of triptorelin (Decapeptyl, Ipsen, France) from day
5 onwards after discontinuation of the oral contraceptive.
This was followed by human menopausal gonadotrophin
(hMG; Menopur, Ferring, Germany) or follicle stimulat-
ing hormone (FSH; either Gonal-F, Serono, Switzerland
or Puregon, Organon, The Netherlands) from day 7 after
discontinuation of the pill onwards. The starting dose was
usually 150 IU, but this dose was adjusted after 7 days of
hMG or FSH administration, according to the individual
response of the patient. Known poor responders were
started on 300 IU of hMG or FSH daily. The follicular
phase was monitored by means of transvaginal ultra-
sound scanning of the ovaries and serum estradiol meas-
urement if judged necessary. An injection of 5,000 or
10,000 IU human chorionic gonadotrophin (hCG; Preg-
nyl, Organon, The Netherlands) was administered when
half of all mature follicles had reached a mean diameter of
at least 20 mm, measured in two planes. Oocyte retrieval
was scheduled 34 to 36 hrs after hCG administration.
Oocytes were denuded enzymatically by a brief exposure
of the cumulus-oocyte complexes to 80 IU/ml hyaluroni-
dase (Type VIII; Sigma Chemical Co., Bornem, Belgium),
followed by mechanical denudation approximately 1 to 2
hrs after oocyte collection. The nuclear status of denuded
oocytes was subsequently recorded. GV oocytes were not
considered for ICSI. MI oocytes were defined as those
oocytes in which no GV and no first polar body were visi-
ble. These oocytes were put in culture to mature. The cul-
Table 1: Comparison of fertilization and embryonic development between in vitro and in vivo matured sibling oocytes
In vitro matured MI oocytes In vivo matured sibling oocytes (control)
Total N° of oocytes injected 129 339
N° (%) of normal fertilized oocytesa 67 (52)* 229 (68)
Embryo development on day 2 (%)b
Excellent 24* 41
Good 27 32
Poor 49* 27
Embryo development on day 3 (%)b
Excellent 22* 38
Good 28 32
Poor 50* 30
* Statistically different between columns (p < 0.05).
a Normal fertilized oocytes were defined as oocytes containing 2 pronuclei en 2 polar bodies.
b The proportions of excellent, good and poor embryos are expressed per total number of embryos obtained on day 2 or day 3.Reproductive Biology and Endocrinology 2005, 3:71 http://www.rbej.com/content/3/1/71
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ture medium for in vitro maturation (IVM) was either
Sydney IVF Fertilization Medium (Cook, Ltd., Limerick,
Ireland) or Early Cleavage Medium (Irvine Scientific,
Brussels, Belgium).
MI oocytes were left to mature until the time when ICSI
for the particular patient was carried out. This was in a
time-frame of 2 to 11 hrs after oocyte retrieval (day 0). In
exceptional cases, when the patient did not have any
mature oocyte at the scheduled time of ICSI, MI oocytes
were left to mature overnight and, when matured, were
injected between 19 to 26 hrs after oocyte retrieval (day
1).
In vivo and/or in vitro matured oocytes were injected with
patient's sperm. Sperm preparation for ICSI and details
for the microinjection procedure have been described
elsewhere [10]. After injection, oocytes were cultured in
either Sydney IVF Cleavage Medium (Cook) or Early
Cleavage Medium.
Embryo evaluation and transfer
Assessment of fertilization took place between 16 to 20
hrs after ICSI. Embryos were evaluated based on the
number of blastomeres and the degree of fragmentation.
Embryos with less than 10% anucleated fragments were
classified as 'excellent'. Embryos with either 10–20% or
>20% anucleated fragments were classified as 'good' and
'poor' quality embryos, respectively. Embryos with at least
one blastomere with more than one nucleus were classi-
fied as multinucleated embryos and were considered as
'poor' quality embryos as well, regardless of the degree of
fragmentation.
Transfer of embryos was carried out on day 2 or day 3.
Embryos from in vitro matured MI oocytes were chosen
for transfer only when no other good quality embryos
from MII oocytes were available. The number of embryos
transferred was limited by Belgian law based on female
age, cycle number and embryo quality [11].
Pregnancy was diagnosed by the detection of a positive
serum hCG at least 14 days after embryo transfer, fol-
lowed by a rise in hCG levels. All patients received a trans-
vaginal ultrasound scan between 6 and 7 weeks of
pregnancy to differentiate between biochemical and clin-
ical (presence of an intra-uterine gestational sac with fetal
heart beat) pregnancies and to diagnose ectopic implanta-
tions. All pregnancies were monitored further by transvag-
inal ultrasound until 12 weeks of amenorrhoea.
Statistical analysis
For comparison among groups, results were analyzed with
Chi-square and Fisher's exact test when appropriate.
When the P value was <0.05, the difference was consid-
ered significant.
Results
Patient and cycle characteristics
In the year 2004, 180 patients underwent 187 ICSI cycles
in which maximum 6 MII oocytes and at least one MI
oocyte were retrieved. This is 12.7% of the total number
of ICSI cycles performed in our infertility center during
the same year. The mean age of the patients was 35.9 ±
4.67 years (range 25–48).
A total of 1208 oocytes were collected. Three hundred of
these oocytes were at the MI stage at the moment of oocyte
denudation (24.8%; mean of 1.6 MI oocytes/cycle; range
1–6). Hundred thirty-two oocytes were at the GV stage
(10.9%) and 80 oocytes (6.6%) were degenerated or dam-
aged at the moment of denudation.
Comparison between in vitro matured MI oocytes and in 
vivo matured oocytes
Overall, 43% (129/300) of MI oocytes matured to the MII
stage. Maturation and injection of at least one MI oocyte
was achieved in approximately half of the ICSI cycles
(55%; n = 102). In vivo matured sibling MII oocytes,
retrieved in the same treatment cycles, were injected in
parallel and served as the control group. ICSI was per-
formed with fresh ejaculate in 81.4% of the cycles and
with frozen ejaculate in 9.8% of the cycles. Frozen epidi-
Table 2: Comparison of maturation rates, fertilization rates and embryo development between different time periods of IVM
Time interval of 
IVM
N° of MI oocytes N° (%) of in vitro 
matured oocytes
N° (%) of fertilized 
oocytes
N° (%) of excellent 
+ good quality 
embryos on Day 2 
(c)
N° (%) of excellent 
+ good quality 
embryos on Day 3
2 to 4 hrs 147 60 (41) 26 (43)a 15 (58) 14 (61)
>4 to 7 hrs 136 57 (42) 31 (54)a 15 (48) 9 (38)
>7 to 11 hrs 9 6 (67) 6 (100)b 3 (50) 2 (40)
19 to 26 hrs 8 6 (75) 4 (67)ab 1 (25) 2 (100)
a,b Different letters indicate significant differences within columns (p < 0.05).
c Thirteen embryos were transferred on day 2.Reproductive Biology and Endocrinology 2005, 3:71 http://www.rbej.com/content/3/1/71
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dymal or testicular spermatozoa were used in respectively
1.0% and 7.8% of the cycles.
The results of fertilization and embryo development in
the two groups of oocytes (IVM + control) are presented
in Table 1. The fertilization rate of matured MI oocytes
was significantly lower compared to the fertilization rate
of in vivo matured oocytes (52% versus 68%, P < 0.05).
Also the embryo quality was different between the two
groups. In the in vitro matured group, significantly less
embryos of excellent quality and more embryos of poor
quality were obtained compared to the in vivo matured
group. This was observed on day 2 (p < 0.05) as well as on
day 3 (p < 0.05).
Comparison between different time periods of IVM
A second evaluation of the results was done by splitting
up the period of IVM, between collection of the oocytes
and the time of ICSI, in different time intervals (Table 2).
A number of 147 oocytes, coming from 100 ICSI cycles,
were evaluated for maturity within 2–4 hrs of IVM culture,
136 oocytes (77 ICSI cycles) within >4–7 hrs of culture, 9
oocytes (5 ICSI cycles) within >7–11 hrs of culture, and 8
oocytes (5 ICSI cycles) were left to mature overnight and
were evaluated the day after retrieval, between 19–26 hrs
of culture. A time-dependent increase in the progression
to maturation was noted, ranging from 41% mature
oocytes after 2–4 hrs of IVM to 75% after 19–26 hrs of
IVM, but this trend was not statistically different. The fer-
tilization rate in the group of >7–11 hrs of IVM (100%)
was significantly higher compared to 2–4 hrs of IVM
(43%) and >4–7 hrs of IVM (54%) (p < 0.05), but not to
19–26 hrs of IVM (67%). There was no difference between
the number of excellent and good quality embryos in the
different IVM time interval groups.
Embryo transfer, clinical pregnancy and implantation 
rates
The most important parameter to evaluate whether the
use of in vitro matured MI oocytes has a clinical benefit is
the pregnancy outcome. Table 3 represents the results of
embryo transfer, clinical pregnancy and implantation
rates. A distinction was made between cycles in which at
least one MI oocyte was matured in vitro (n = 102) and
ICSI cycles with no matured MI oocytes (n = 85). The
group of cycles with matured MI oocytes was further split-
up in 3 groups: 1) transfers involving exclusively embryos
derived from in vitro matured MI oocytes, 2) mixed trans-
fers and 3) transfers involving exclusively embryos
derived from in vivo matured MII oocytes. A double
embryo transfer involving embryos exclusively derived
from MI oocytes resulted in a singleton pregnancy and the
birth of a healthy baby girl. This baby originated from an
oocyte that was injected after 22 hrs of IVM. There was no
statistical difference between clinical pregnancy rates and
embryo implantation rates in the three groups. However,
when the numbers of exclusively MI and mixed transfers
were pooled and compared to exclusively MII transfers,
the clinical pregnancy rates (8.8% versus 27.0%) and
embryo implantation rates (5.6% versus 15.1%) were sig-
nificantly lower in the former group (p < 0.05).
Total MI oocyte utilization rate
Forty-two embryos derived from normally fertilized in
vitro matured oocytes were used for transfer and 9
embryos were cryopreserved. This means that 51 out of 67
embryos originating from MI oocytes were used. The total
Table 3: Clinical pregnancy and implantation rates in cycles with maximum 6 MII oocytes
cycles with at least one MI oocyte matured (n = 102) cycles with no MI 
oocyte matured
(n = 85)
Total (n = 187)a
Exclusively 
embryos derived 
from MI oocytes
Mixed transfers Exclusively 
embryos derived 
from sibling MII 
oocytes
N° of transfers 13 21 63 81 178
N° of embryos 
transferred
17 54 119 141 331
N° (%) of clinical 
pregnancies per 
embryo transfer
1 (7.7) 2 (9.5) 17 (27.0) 15 (18.5) 35 (19.7)
N° (%) of implanted 
embryos
1 (5.9) 3 (5.6)b 18 (15.1)b 15 (10.6) 37 (11.2)
No statistical difference between columns.
a In 9 ICSI cycles, no embryo transfer was done.
b A twin pregnancy was obtained in these groups.Reproductive Biology and Endocrinology 2005, 3:71 http://www.rbej.com/content/3/1/71
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MI oocyte utilization rate (= percentage of embryos trans-
ferred and frozen per fertilized oocyte) was 76%.
Discussion
The present study aimed to analyze, for the first time, the
clinical benefit of MI oocytes in a selected group of
patients with a low number of mature oocytes at retrieval.
To achieve this goal, we selected ICSI cycles in which a
maximum of 6 mature oocytes and at least one MI oocyte
were obtained at oocyte retrieval. The results show that
fertilization rate and developmental capacity of the
embryos was significantly reduced in IVM oocytes com-
pared with control sibling oocytes. One live birth
obtained after transfer of embryos exclusively derived
from IVM oocytes illustrates that the use of MI oocytes is
not of major issue in IVF programs, but may be an option
for patients with low numbers of MII oocytes.
A low number of oocytes at retrieval might be a result of
low ovarian response to gonadotrophin stimulation. Low
response to stimulation occurs in approximately 10% of
the ART population [12]. There is no universally accepted
definition for low response. One of the criteria is the
number of oocytes retrieved. Faber et al. [13] used an
oocyte retrieval rate of ≤ 4 mature oocytes as cut-off limit,
while De Sutter et al. [14] and Moreno et al. [15] catego-
rized < 5 and ≤ 6 oocytes retrieved, respectively, as low
responding patients, without distinguishing mature and
immature oocytes. Based on these different definitions, it
can be concluded that the patients in our study can be cat-
egorized as 'relatively poor responders'. In each cycle of
this study, at least one MI oocyte was present. The propor-
tion of immature oocytes (GV +MI = 35.7%) in this group
of relatively poor responding patients is high compared to
the percentages described in the literature after ovarian
stimulation in a non-selected group of patients (15–20%;
[1,2]) and, as a consequence, the total MI oocyte utiliza-
tion rate of 76% shows that embryos from in vitro
matured MI oocytes were used at high frequency for trans-
fer or cryopreservation.
In the majority of the ICSI cycles, the maturation status of
the MI oocytes was checked between 2 to 7 hours after
oocyte retrieval. Within this time-frame, 41.3% of the col-
lected MI oocytes extruded their polar body. These matu-
ration rates are comparable with those achieved by others
working with MI oocytes retrieved from stimulated cycles.
Chian et al. [16] obtained a maturation rate of 46.1% and
52.0% after 6 hrs of in vitro culture and Strassburger et al.
[8] obtained 45.1% matured oocytes after 4 hrs of culture.
Other studies describe lower maturation rates, like the
study of Devos et al. [6] (26.7% maturation after 4 hrs of
culture) and the study of Chen et al. [9] (16.4% matura-
tion after 9 hrs of culture). Variations in maturation rates
between studies might be explained by different starting
and ending points for in vitro maturation. Also the culture
conditions, the use of more suitable types of media and/
or the addition of serum, growth factors and hormones
might influence maturation rates, subsequent fertilization
and embryo development of in vitro matured oocytes [16-
18]. The group of Balakier et al. [7] performed an exact
time recording of polar body extrusion during IVM of MI
oocytes. They found that the highest fertilization rate and
the lowest incidence of multinucleation were obtained
when injection of the oocytes was performed between 3 to
6 hrs after extrusion of the first polar body. This indicates
that oocyte maturation is not completed upon reaching
the MII stage. In the present study, we did not perform an
accurate kinetic experiment, but proper timing of polar
body extrusion as well as injection may enhance the out-
come of in vitro matured oocytes.
Whatever the conditions of in vitro maturation applied,
our study and the majority of other studies show consist-
ently lower fertilization rates of in vitro matured MI
oocytes compared to sibling in vivo matured oocytes [6-
8]. The proportion of poor quality embryos was higher
after in vitro maturation. This is in accordance with other
publications, which describe more cleavage arrest [7,8], a
higher number of multinucleated blastomeres [7] and a
reduced development to the blastocyst stage [9] after IVM.
On the contrary, the study of Devos et al. [6], performed
on a large group of 896 ICSI cycles, found the same pro-
portions of excellent and fair quality embryos after IVM
compared to in vivo matured oocytes. This might be
explained by the IVM incubation time of maximum 4 hrs
applied in this study. Longer IVM incubation times could
result in oocyte ageing. However, we were not able to find
a statistical difference in fertilization rate and embryo
quality between the different IVM time intervals in the in
vitro matured group, although a larger sample would be
necessary for a more conclusive statement in the IVM time
intervals of >7–11 hrs and 19–26 hrs. Nevertheless, of
special interest was the fact that the live birth we obtained
from exclusively IVM oocytes originated from an oocyte
that was matured in vitro for a period of 22 hrs.
Conclusion
We may conclude that the use of in vitro matured MI
oocytes can be of benefit to obtain pregnancy in patients
with a low number of MII oocytes. IVM culture conditions
and time schedule for ICSI must be refined to achieve
optimum fertilization and development.
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